- Home
- NNNN vs JANX Comparison
NNNN vs JANX Comparison
Compare NNNN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNNN
- JANX
- Stock Information
- Founded
- NNNN 2021
- JANX 2017
- Country
- NNNN Germany
- JANX United States
- Employees
- NNNN N/A
- JANX N/A
- Industry
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- NNNN Health Care
- JANX Health Care
- Exchange
- NNNN Nasdaq
- JANX Nasdaq
- Market Cap
- NNNN 2.2B
- JANX 1.8B
- IPO Year
- NNNN 2025
- JANX 2021
- Fundamental
- Price
- NNNN $27.36
- JANX $29.24
- Analyst Decision
- NNNN
- JANX Buy
- Analyst Count
- NNNN 0
- JANX 11
- Target Price
- NNNN N/A
- JANX $77.40
- AVG Volume (30 Days)
- NNNN 39.8K
- JANX 1.2M
- Earning Date
- NNNN 04-28-2026
- JANX 11-06-2025
- Dividend Yield
- NNNN N/A
- JANX N/A
- EPS Growth
- NNNN N/A
- JANX N/A
- EPS
- NNNN 0.06
- JANX N/A
- Revenue
- NNNN $8,185,146.00
- JANX $10,000,000.00
- Revenue This Year
- NNNN N/A
- JANX N/A
- Revenue Next Year
- NNNN N/A
- JANX $89.91
- P/E Ratio
- NNNN $503.50
- JANX N/A
- Revenue Growth
- NNNN 21.95
- JANX N/A
- 52 Week Low
- NNNN $5.18
- JANX $21.73
- 52 Week High
- NNNN $55.65
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- NNNN 54.26
- JANX 57.37
- Support Level
- NNNN $12.93
- JANX $26.96
- Resistance Level
- NNNN $25.20
- JANX $30.47
- Average True Range (ATR)
- NNNN 4.99
- JANX 1.90
- MACD
- NNNN 1.61
- JANX 0.03
- Stochastic Oscillator
- NNNN 73.40
- JANX 78.49
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.